TY - JOUR
T1 - The effect of tumor burden on ornithine decarboxylase activity in mice
AU - Saydjari, Rami
AU - Alexander, Robert W.
AU - Upp, James R.
AU - Poston, Graeme J.
AU - Barranco, Sam C.
AU - Townsend, Courtney M.
AU - Thompson, James C.
N1 - Funding Information:
Supported by grants from the National Institutes of Health (5R37 DK 15241 and PO1 DK 35608), the American Cancer Society (PDT-220), the National Cancer Institute (RO1 CA 15397), and in conjunction with the Walls Medical Research Foundation. The DFMO was the generous gift of W.J. Hudak, Ph.D., Manager of Research Information, Merrelt Research Center, Cincinnati, OH. The authors thank Pamella J. Ford for her excellent technical assistance, and Kelly Lee for her assistance in the preparation of this manuscript.
Funding Information:
**Dr. Poston is a recipient of the Hurst Traveling Fellowship of the British Digestive Foundation, Ethicon Foundation travel grant and Wellcome Foundation travel grant.
PY - 1991
Y1 - 1991
N2 - Polyamines are essential for cell growth of normal and neoplastic tissue. αDifluoromethylornithine (DFMO) is a known irreversible inhibitor or ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. The purpose of this study was to examine the effects of tumor burden on ODC in tissues of tumorbearing compared with tumor-free mice. Twenty-eight male Balb/c mice were divided into four groups of 7 each. Groups 1 and 2 were inoculated subcutaneously with 10 X 106 MC-26 mouse colon adenocarcinoma cells. Groups 3 and 4 were kept as tumor-free controls. Ten days after inoculation, groups 2 and 4 were injected with DFMO (200 mg/kg) intraperitoneally (IP) while Groups 1 and 3 received saline. Two hours after the injection of DFMO the animals were sacrificed. The tumor, pancreas, kidney, and liver were excised and analyzed for ODC activity. DFMO caused a significant reduction (compared with controls that did not receive DFMO) in the ODC activity of tumors; however, ODC activity of the kidney, pancreas, and liver of tumor-bearing mice was not affected. Additionally, the basal ODC activity in the kidney, liver, and pancreas of tumor-bearing mice was significantly lower compared with tumor-free controls. DFMO lowered ODC activity in the kidney, pancreas, and liver of tumor-free mice. These results suggest that the presence of MC-26 tumor causes systemic effects that alter ODC activity and the response to a known inhibitor of ODC.
AB - Polyamines are essential for cell growth of normal and neoplastic tissue. αDifluoromethylornithine (DFMO) is a known irreversible inhibitor or ornithine decarboxylase (ODC), the rate-limiting enzyme in polyamine biosynthesis. The purpose of this study was to examine the effects of tumor burden on ODC in tissues of tumorbearing compared with tumor-free mice. Twenty-eight male Balb/c mice were divided into four groups of 7 each. Groups 1 and 2 were inoculated subcutaneously with 10 X 106 MC-26 mouse colon adenocarcinoma cells. Groups 3 and 4 were kept as tumor-free controls. Ten days after inoculation, groups 2 and 4 were injected with DFMO (200 mg/kg) intraperitoneally (IP) while Groups 1 and 3 received saline. Two hours after the injection of DFMO the animals were sacrificed. The tumor, pancreas, kidney, and liver were excised and analyzed for ODC activity. DFMO caused a significant reduction (compared with controls that did not receive DFMO) in the ODC activity of tumors; however, ODC activity of the kidney, pancreas, and liver of tumor-bearing mice was not affected. Additionally, the basal ODC activity in the kidney, liver, and pancreas of tumor-bearing mice was significantly lower compared with tumor-free controls. DFMO lowered ODC activity in the kidney, pancreas, and liver of tumor-free mice. These results suggest that the presence of MC-26 tumor causes systemic effects that alter ODC activity and the response to a known inhibitor of ODC.
UR - http://www.scopus.com/inward/record.url?scp=0025816364&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025816364&partnerID=8YFLogxK
U2 - 10.3109/07357909109084639
DO - 10.3109/07357909109084639
M3 - Article
C2 - 1884248
AN - SCOPUS:0025816364
SN - 0735-7907
VL - 9
SP - 415
EP - 419
JO - Cancer Investigation
JF - Cancer Investigation
IS - 4
ER -